Uncategorized
R&D expenses increase as Ophthotech advances Fovista clinical trials
Burgeoning patient enrollment for clinical trials of Fovista, Ophthotech’s leading product candidate, largely shaped the company’s balance sheet for the first quarter of 2015.During a company-sponsored conference call to report first quarter financial results and ongoing enrollment in the trials, CEO David R. Guyer, MD, discussed efforts to advance Fovista, an anti-PDGF agent, in the treatment of wet age-related macular degeneration.